MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD BDRX 深 沪
等待开盘 09-27 09:30:00 美东时间
6.35
-0.260
-3.93%
华盛通- 最 高6.5986
- 今 开6.54
- 成交量 1.16万股
- 最 低 6.35
- 昨 收 6.61
- 总市值 393.38万
- 52周最高 108.90
- 市盈率 静 --
- 换手率 1.88%
- 52周最低 5.0001
- 委 比 -82.18%
- 总股本 61.95万
- 历史最高 159417654.2112
- 量 比 0.77
- 振 幅 3.76%
- 历史最低 6.35
- 每 手 1
- 风险率 20.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biodexa Pharmaceuticals Advances Serenta Trial and Secures Financial Backing
An announcement from Biodexa Pharmaceuticals ( ($BDRX) ) is now available. Biod...
09-12 21:33
Biodexa Pharmaceuticals GAAP EPS of -£0.0002
Biodexa Pharmaceuticals press release (NASDAQ:BDRX): 1H GAAP EPS of -£0.0002. Net cash used in operating activities (after changes in working capital) in 1H25 was £3.30 million (1H24: £4.81 million). ...
09-12 20:43
Biodexa Pharmaceuticals Begins Phase 3 Trial for FAP Treatment
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On August 18...
08-18 20:57
Biodexa Pharmaceuticals Implements ADR Ratio Change
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an update. On July 31, 2025, ...
07-31 21:59
Biodexa Pharma Advances Development eRapa, Oral Tablet Formulation Of Rapamycin, To Treat FAP Non-Surgically
Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company, reports making significant progress in developing eRapa, an oral tablet formulation of rapamycin, to treat FAP non-surgically. eRapa
07-28 19:10
ADR Ratio Change
On July 15, 2025, Biodexa Pharmaceuticals PLC announced a ratio change for its American Depositary Receipts (ADR), adjusting from 1 ADR representing 10,000 ordinary shares to 1 ADR representing 100,000 ordinary shares, effective July 31, 2025. ADR holders must exchange 10 old ADRs for 1 new ADR. This change aims to align the ADR price with Nasdaq's $1.00 minimum bid price requirement, though success is not guaranteed. Forward-looking statements a...
07-15 20:30
Biodexa Pharma Files CTA With EMA For Serenta Trial In Patients With Familial Adenomatous Polyposis
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial inFamilial Adenomatous Polyposis (FAP)Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical
07-14 20:35
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has activated the first clinical study site for its Phase 3 Serenta trial, focusing on Familial Adenomatous Polyposis (FAP). The trial evaluates the safety and efficacy of eRapa, an mTOR inhibitor, offering a potential new treatment for FAP, a rare genetic condition with high risks of colorectal cancer. Biodexa received $20 million in grant funding from CPRIT to support this program. The trial is now enrolling participants...
06-25 12:30
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has named its upcoming Phase 3 study for Familial Adenomatous Polyposis (FAP) "Serenta" and launched a dedicated website, www.serentatrial.com, to provide information for patients and healthcare professionals. Serenta highlights Biodexa's commitment to supporting the FAP community. The study focuses on eRapa, an oral mTOR inhibitor designed to address the poor bioavailability and toxicity of existing rapamycin forms. Addit...
06-23 12:30
Market-Moving News for June 18th
SRRK: 23% | Scholar Rock shares are trading higher after a study showed its new drug combination preserves muscle during tirzepatide-induced weight loss. RELI: 70% | Reliance Global shares are trading
06-18 19:29
